Golden State Equity Partners Raises Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Golden State Equity Partners increased its stake in Thermo Fisher Scientific by 210.8% during the second quarter, resulting in holdings worth approximately $1.22 million.
• Insider transactions included CEO Marc N. Casper selling 10,000 shares for around $5 million, indicating a 7.99% decrease in his ownership.
• Analysts have mixed views on the stock, with several brokerages adjusting their ratings, including a downgrade from "buy" to "hold" by Wall Street Zen.

Golden State Equity Partners boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 210.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,018 shares of the medical research company's stock after buying an additional 2,047 shares during the period. Golden State Equity Partners' holdings in Thermo Fisher Scientific were worth $1,224,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Intergy Private Wealth LLC grew its position in Thermo Fisher Scientific by 5.8% during the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after buying an additional 23 shares during the period. Root Financial Partners LLC grew its position in Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after buying an additional 24 shares during the period. Rossmore Private Capital grew its position in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock valued at $2,315,000 after buying an additional 24 shares during the period. Finally, ARS Wealth Advisors Group LLC boosted its position in Thermo Fisher Scientific by 1.6% during the first quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company's stock worth $778,000 after purchasing an additional 25 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO traded down $5.04 on Monday, reaching $474.54. The company had a trading volume of 2,352,185 shares, compared to its average volume of 1,557,193. The business has a 50 day simple moving average of $472.99 and a 200 day simple moving average of $448.55. The company has a market cap of $179.19 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TMO shares. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.